Form 4: Amgen Director Holley Receives Equity Grant

Amgen Inc. Director Charles M. Holley reported the acquisition of 147.4517 shares of common stock through an equity incentive program.

Summary

• Charles M. Holley, a Director of Amgen Inc. (AMGN), acquired 147.4517 shares of common stock on August 8, 2025.
• The shares were acquired at a price of $0, indicating they were part of a grant or vesting event.
• The acquisition was made pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, and the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan.
• The Restricted Stock Units (RSUs) vested immediately and are paid in shares of the company's common stock on a one-to-one basis, with an option for deferral.
• The acquired shares include 1,294 Dividend Equivalents (DEs) granted under the Director Program, subject to a dividend reinvestment plan, paid out in common stock and cash for fractional amounts.
• Following this transaction, Charles M. Holley beneficially owns 11,469.6259 shares directly and 1,260 shares indirectly through the Holley Family Trust.

Sentiment

Score: 7

Explanation: The filing indicates a director's receipt of equity compensation, which is generally positive as it aligns management's interests with shareholders. It is a routine compensation event and not indicative of significant operational or financial changes.

Positives

• A director's acquisition of shares, even through a grant, aligns their interests with those of shareholders, promoting long-term value creation.
• The existence of a Director Incentive Program and Equity Incentive Plan demonstrates a structured approach to executive and director compensation, utilizing equity to incentivize performance and retention.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing details a routine insider transaction related to director compensation, which is a common practice across publicly traded companies in all industries, including the biotechnology and pharmaceutical sector. It reflects the standard mechanism for compensating board members with equity to align their interests with shareholders.

Stakeholder Impact

• Shareholders: The equity grant to a director reinforces alignment between the board's interests and shareholder value, potentially leading to more shareholder-friendly decisions.
• Employees: While not directly impacting employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Key Dates

Keywords

Amgen, AMGN, Form 4, Insider Transaction, Director Compensation, Stock Grant, RSU, Dividend Equivalents, Equity Incentive Plan